{"entity":{"id":"nct05394103","kind":"trial","name":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in metastatic cancer, run by Qurient Co., Ltd., now recruiting.","summary":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05394103 by Qurient Co., Ltd., with 130 participants planned, started 2022-08-30 and due to reach its primary completion in 2025-12-30. Interventions recorded: Q901, KEYTRUDA® (pembrolizumab). Conditions listed: Advanced Cancer, Metastatic Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05394103","url":"https://clinicaltrials.gov/study/NCT05394103"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["qurient"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05394103","phase":"1/2","setting":"A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose","sponsor":"Qurient Co., Ltd.","participation":[{"nct":"NCT05394103","source":"https://clinicaltrials.gov/study/NCT05394103","fetchedAt":"2026-10-07T16:53:41.225Z","studySha256":"19faea09ae41051faeb19e1534729cf3ebc55f385dd00a4fc3c23e15337396df","overallStatus":"RECRUITING","lastUpdatePosted":"2025-08-17","leadSponsor":"Qurient Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":130,"enrolmentType":"ESTIMATED","siteCount":11,"recruitingSiteCount":9,"countries":["South Korea","United States"]}],"started":"2022-08-30","startedType":"actual","enrolled":130,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05394103/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"qurient","kind":"company","name":"Qurient","route":"/companies/qurient/"}]}}